Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Novartis Ends License Agreement for Cancer Drug with Allarity Due to Non-Payment
Details : The agreement provided Allarity with TKI258 (dovitinib), an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors, for the treatment of renal cancer.
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2024
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Stenoparib is a dual-targeted inhibitor of PARP 1, 2 and tankyrase 1, 2 where dovitinib is a pan-tyrosine kinase inhibitor. The combination may increase the chances of cancer apoptosis and providing synergistic, enhanced antitumor activity.
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
Details : The DRP® platform has proven its ability to provide a statistically significant prediction of clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined including ongoing, prospective Phase 2 trials of St...
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2022
Lead Product(s) : Dovitinib,Stenoparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allarity Therapeutics Provides Update on Dovitinib Program
Details : Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA.
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NDA is supported by Allarity’s previously-filed pre-market approval submission to the FDA for the Dovitinib-DRP® companion diagnostic to select RCC patients most likely to respond to the drug.
Brand Name : Dovitinib-DRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 22, 2021
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Lonza will leverage its capabilities for commercial manufacturing of small-molecules including Dovitinib and oral solid dosage forms to provide Allarity with cGMP compliant drug product supply and regulatory support towa...
Brand Name : Dovitinib-DRP
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 23, 2021
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with ...
Brand Name : Dovitinib-DRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : Dovitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Allarity’s unique and clinically validated DRP® biomarker technology makes it possible to predict whether a particular cancer patient is likely to benefit from treatment with dovitinib, in addition to a broad range of anti-cancer drugs.
Brand Name : Dovitinib-DRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2021
Details : Allarity’s focus on pediatric osteosarcoma development is based on the results of two previously reported preclinical studies in which treatment with dovitinib, compared to control treatment (sucrose solution lacking dovitinib).
Brand Name : TKI258
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2021
Details : The e-Poster provides new details of the Dovitinib-DRP® companion diagnostic, which is used to select cancer patients most likely to respond to the pan-targeted kinase inhibitor (pan-TKI) dovitinib.
Brand Name : Dovitinib-DRP
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2021
LOOKING FOR A SUPPLIER?